A case of strongyloides stercoralis and mesenteric tuberculous infection with acute abdominal pain in an HIV-positive patientDE LA ROSA, Guy R; KULIEV, Agadadash; BARNETT, Ben J et al.Scandinavian journal of infectious diseases. 2002, Vol 34, Num 9, pp 696-697, issn 0036-5548Article

Native valve endocarditis due to Bartonella henselae in a middle-aged human immunodeficiency virus-negative womanDE LA ROSA, Guy R; BARNETT, Ben J; ERICSSON, Charles D et al.Journal of clinical microbiology (Print). 2001, Vol 39, Num 9, pp 3417-3419, issn 0095-1137Article

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trialJACOBSON, Ira M; DORE, Gregory J; OUWERKERK-MAHADEVAN, Sivi et al.Lancet (British edition). 2014, Vol 384, Num 9941, pp 403-413, issn 0140-6736, 11 p.Article

Virological analysis of once-daily and twice-daily darunavir/ritonavir in the ODIN trial of treatment-experienced patientsLATHOUWERS, Erkki; DE LA ROSA, Guy; VAN DE CASTEELE, Tom et al.Antiviral therapy (London). 2013, Vol 18, Num 3, pp 289-300, issn 1359-6535, 12 p.Article

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trialMANNS, Michael; MARCELLIN, Patrick; LENZ, Oliver et al.Lancet (British edition). 2014, Vol 384, Num 9941, pp 414-426, issn 0140-6736, 13 p.Article

Metabolic Effects of Darunavir/Ritonavir Versus Atazanavir/Ritonavir in Treatment-Naive, HIV Type 1-Infected Subjects over 48 WeeksABERG, Judith A; TEBAS, Pablo; TURNER OVERTON, Edgar et al.AIDS research and human retroviruses. 2012, Vol 28, Num 10, pp 1184-1195, issn 0889-2229, 12 p.Article

Simeprevir (TMC435) With Pegylated Interferon/Ribavirin in Patients Coinfected With HCV Genotype 1 and HIV-1: A Phase 3 StudyDIETERICH, Douglas; ROCKSTROH, Jürgen Kurt; PEETERS, Monika et al.Clinical infectious diseases. 2014, Vol 59, Num 11, pp 1579-1587, issn 1058-4838, 9 p.Article

Darunavir Outcomes Study: Comparative Effectiveness of Virologic Suppression, Regimen Durability, and Discontinuation Reasons for Three-Class Experienced Patients at 48 WeeksWILLIG, James H; ABAN, Inmaculada; SAAG, Michael S et al.AIDS research and human retroviruses. 2010, Vol 26, Num 12, pp 1279-1285, issn 0889-2229, 7 p.Article